JPH0647545B2 - 医薬用組成物 - Google Patents
医薬用組成物Info
- Publication number
- JPH0647545B2 JPH0647545B2 JP59191391A JP19139184A JPH0647545B2 JP H0647545 B2 JPH0647545 B2 JP H0647545B2 JP 59191391 A JP59191391 A JP 59191391A JP 19139184 A JP19139184 A JP 19139184A JP H0647545 B2 JPH0647545 B2 JP H0647545B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- defibrotide
- peripheral
- arteropathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
- 230000002093 peripheral effect Effects 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000007972 injectable composition Substances 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 1
- JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 abstract description 12
- 229960004120 defibrotide Drugs 0.000 abstract description 12
- 200000000007 Arterial disease Diseases 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 4
- 230000001732 thrombotic effect Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000003143 atherosclerotic effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960005356 urokinase Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 208000021328 arterial occlusion Diseases 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000008069 intimal proliferation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT22855A/83 | 1983-09-12 | ||
| IT22855/83A IT1170214B (it) | 1983-09-12 | 1983-09-12 | Composizione farmaceutica per la cura delle arteriopatie periferiche |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6169722A JPS6169722A (ja) | 1986-04-10 |
| JPH0647545B2 true JPH0647545B2 (ja) | 1994-06-22 |
Family
ID=11201215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59191391A Expired - Lifetime JPH0647545B2 (ja) | 1983-09-12 | 1984-09-12 | 医薬用組成物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US5081109A (enExample) |
| EP (1) | EP0137543B1 (enExample) |
| JP (1) | JPH0647545B2 (enExample) |
| AT (1) | ATE55695T1 (enExample) |
| BE (1) | BE900564A (enExample) |
| CH (1) | CH661870A5 (enExample) |
| DE (1) | DE3433328A1 (enExample) |
| IT (1) | IT1170214B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1223322B (it) * | 1987-10-23 | 1990-09-19 | Crinos Industria Farmaco | Metodo per prevenire la formazione di coaguli sanguigni nel circuito extracorporeo di apparecchi di dialisi a composizione utile per esso |
| IT1231509B (it) * | 1989-09-07 | 1991-12-07 | Crinos Industria Farmaco | Composizione farmceutica ad uso topico per la terapia della fragilita' capillare. |
| US6699985B2 (en) * | 1991-08-21 | 2004-03-02 | Arsinur Burcoglu | Method of treating HIV infection and related secondary infections thereof |
| DE19610345C1 (de) | 1996-03-18 | 1997-11-20 | Krupp Vdm Gmbh | Katalysator zur Oxidation von Abwasserverunreinigungen mittels Persäuren und/oder Wasserstoffperoxid |
| HK1044896A1 (zh) * | 1997-04-28 | 2002-11-08 | Burcoglu Arsinur | 治疗hiv感染和与之有关的继发感染的方法 |
| ITMI20031714A1 (it) * | 2003-09-05 | 2005-03-06 | Gentium Spa | Formazioni ad azione antitumorale. |
| CA2598072C (en) * | 2005-03-03 | 2016-05-03 | Massimo Iacobelli | Formulations with anti-tumour action |
| SI1891952T1 (sl) * | 2006-05-04 | 2012-02-29 | Lek Pharmaceuticals, D.D. | Farmacevtski sestavek, ki vsebuje olmesartan medoksomil |
| EP1872787A1 (en) * | 2006-06-27 | 2008-01-02 | Gentium S.p.A. | Use of defibrotide for the inhibition of heparanase |
| EP1982722A1 (en) * | 2007-04-16 | 2008-10-22 | Gentium S.p.A. | Use of oligotide for the treatment of renal diseases |
| EP2103689A1 (en) | 2008-03-19 | 2009-09-23 | Gentium S.p.A. | Synthetic phosphodiester oligonucleotides and therapeutical uses thereof |
| EP2637672B1 (en) | 2010-11-12 | 2018-08-22 | Gentium S.r.l. | Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd). |
| DK2864496T4 (da) | 2012-06-22 | 2021-01-04 | Gentium S R L | Euglobulin-baseret fremgangsmåde til bestemmelse af den biologiske aktivitet af defibrotid |
| EP3026122A1 (en) | 2014-11-27 | 2016-06-01 | Gentium S.p.A. | Cellular-based method for determining the potency of defibrotide |
| MX2020001337A (es) | 2017-08-03 | 2020-09-09 | Jazz Pharmaceuticals Ireland Ltd | Formulaciones que comprenden un acido nucleico en una alta concentracion. |
| KR20210008478A (ko) | 2018-04-12 | 2021-01-22 | 재즈 파마슈티칼즈, 인코포레이티드 | 면역고갈과 관련된 사이토카인 방출 증후군 및 신경독성의 예방 및 치료를 위한 데피브로타이드 |
| WO2020118165A1 (en) | 2018-12-07 | 2020-06-11 | Jazz Pharmaceuticals Ireland Limited | Subcutaneous delivery of high concentration formulations |
| EP4110287A1 (en) | 2020-02-28 | 2023-01-04 | Jazz Pharmaceuticals Ireland Limited | Delivery of low viscosity formulations |
| WO2021212055A1 (en) | 2020-04-17 | 2021-10-21 | Jazz Pharmaceuticals Ireland Limited | Defibrotide treatment for the prevention of organ rejection and injury |
| WO2022234101A1 (en) | 2021-05-06 | 2022-11-10 | Jazz Pharmaceuticals Ireland Limited | Defibrotide for the treatment and prevention of acute respiratory distress syndrome |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2154279A1 (de) * | 1970-11-03 | 1972-05-25 | Crinos Industria Farmaco | Medikamente für das fibrinolytische System |
| IT1043823B (it) * | 1970-11-03 | 1980-02-29 | Prephar | Procedimento per l estrazione di acidi nucleici da organi animali |
| US3899481A (en) * | 1970-11-03 | 1975-08-12 | Crinos Industria Farmaco | Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs |
| US4485105A (en) * | 1978-10-12 | 1984-11-27 | American Cyanamid Company | Method of treating hyperlipidemia with 4-(monoalkylamino)benzoic acid amides |
| GB2043072B (en) * | 1979-02-13 | 1983-11-23 | Symphar Sa | Diphosphonate compounds |
| US4416877A (en) * | 1979-02-13 | 1983-11-22 | Symphar S.A. | Anti-atherosclerotic pharmaceutical compositions containing diphosphonate compounds |
| JPS5675474A (en) * | 1979-11-22 | 1981-06-22 | Chugai Pharmaceut Co Ltd | Nicotinamide derivative and medicine containing the same |
| US4351950A (en) * | 1980-01-02 | 1982-09-28 | Warner-Lambert Company | Anti-arteriosclerotic agents |
| US4450272A (en) * | 1982-05-06 | 1984-05-22 | American Cyanamid Company | Antiatherosclerotic 1-piperazine-thicarboxamides |
| IT1167197B (it) * | 1983-07-25 | 1987-05-13 | Bellon Roger Schoum Rbs Pharma | Impiego della fenpiramina quale farmaco antiaggregante piastrinico,vasodilatatore,antitrombotico e antianginoso |
| IT1170215B (it) * | 1983-09-12 | 1987-06-03 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta |
| IT1206341B (it) * | 1984-02-16 | 1989-04-14 | Crinos Industria Farmaco | Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio. |
-
1983
- 1983-09-12 IT IT22855/83A patent/IT1170214B/it active
-
1984
- 1984-09-07 CH CH4280/84A patent/CH661870A5/it not_active IP Right Cessation
- 1984-09-07 EP EP84201287A patent/EP0137543B1/en not_active Expired - Lifetime
- 1984-09-07 AT AT84201287T patent/ATE55695T1/de active
- 1984-09-11 DE DE19843433328 patent/DE3433328A1/de active Granted
- 1984-09-12 BE BE0/213641A patent/BE900564A/fr not_active IP Right Cessation
- 1984-09-12 JP JP59191391A patent/JPH0647545B2/ja not_active Expired - Lifetime
-
1988
- 1988-07-05 US US07/218,514 patent/US5081109A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP0137543A2 (en) | 1985-04-17 |
| EP0137543A3 (en) | 1987-09-02 |
| IT8322855A0 (it) | 1983-09-12 |
| DE3433328A1 (de) | 1985-03-28 |
| IT1170214B (it) | 1987-06-03 |
| ATE55695T1 (de) | 1990-09-15 |
| DE3433328C2 (enExample) | 1993-08-05 |
| BE900564A (fr) | 1985-01-02 |
| EP0137543B1 (en) | 1990-08-22 |
| JPS6169722A (ja) | 1986-04-10 |
| US5081109A (en) | 1992-01-14 |
| CH661870A5 (it) | 1987-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0647545B2 (ja) | 医薬用組成物 | |
| ES2582376T3 (es) | Método para la mejora de la señalización de islotes en diabetes mellitus y para su prevención | |
| CA2061270C (en) | Method and composition for treating reperfusion injury | |
| CA2288143A1 (en) | Activated protein c formulations | |
| JPH0647546B2 (ja) | 医薬組成物 | |
| ES2267591T3 (es) | Combinaciones farmaceuticas que comprenden un antagonista del receptor p2t y melagatran. | |
| SU1183112A1 (ru) | Способ лечени острой ишемии миокарда | |
| HU227956B1 (en) | Use of factor xa inhibiting oligosaccharide with a platelet antiaggregating agent for treating arterial thrombosis | |
| CZ297317B6 (cs) | Farmaceutická kompozice pro orální pouzití proti peptickému vredu | |
| Perla et al. | Prevention of histamine and surgical shock by cortical hormone (desoxycorticosterone acetate and cortin) and saline | |
| RU2001118854A (ru) | Оптически активное производное пиридил-4н-1,2,4-оксадиазина и его применение при лечении сосудистых заболеваний | |
| McGraw et al. | Sucralfate | |
| JP3792251B2 (ja) | 手術後の悪心および嘔吐の治療のためのグラニセトロンの使用 | |
| HUT76895A (en) | Use of hyaluronic acid for preparing pharmaceutical compns. for treatment of disease and conditions associated with macrophage infiltration | |
| Stone et al. | Nifedipine therapy for recurrent ischemic pain following myocardial infarction | |
| Mersereau et al. | Prevention of bile reflux-induced acute gastric ulceration in the rat by cholestyramine | |
| CA1215323A (en) | Curative composition for buerger's disease | |
| JP3811500B2 (ja) | 動脈硬化の除去のためのヒアルロン酸を含む薬剤組成物 | |
| JPH0415766B2 (enExample) | ||
| US3487150A (en) | Dextran sulphate treatment of peptic ulcers | |
| JP4903694B2 (ja) | 抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用 | |
| JP3280726B2 (ja) | 抗潰瘍剤 | |
| JP2006506377A (ja) | テナトプラゾール及びヒスタミンｈ２受容体拮抗剤を組み合わせた医薬組成物 | |
| JP2548491B2 (ja) | 内膜肥厚の予防、治療剤 | |
| JPH1179991A (ja) | 移植皮膚又は移植組織の壊死防止剤 |